Should You Buy BioRestorative Therapies, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, BioRestorative Therapies, Inc. (BRTX) occupies a solid middle-ground position with a Quality of Company score of 6.3/10. At the current market price of $2.64, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 1 CirclFi valuation models project upside for BioRestorative Therapies, Inc. (BRTX) at $2.64 — the model consensus leans bullish, with a Quality Score of 6.3/10 and Value-Trap risk of 32/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for BioRestorative Therapies, Inc. (BRTX) in 2026?
What Is the Bull Case vs the Bear Case for BioRestorative Therapies, Inc. (BRTX)?
| Bull case — $11.91 target (+351.0%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $2.64 and the median fair value of $11.91 implies +351.0% upside potential. | No active model flags significant downside for BRTX. The Value Trap score of 32/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model targets a fair value of $11.91 (+351.0%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: first-mover advantage in novel targets could provide meaningful support for BioRestorative Therapies, Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does BRTX Compare to Its Biotechnology Peers?
Valuation data pages: CHRS · PHAT · IONS · LXRX · VTGN · NTLA · XBIT · ATXI · CING · EXEL · INCY
Which Other Stocks Score Like BRTX on Quality?
Closest companies to BRTX’s Quality of Company score of 6.3/10, across all industries.
- MSN — Emerson Radio Corp. (QOC 6.3) · analysis
- ONEW — OneWater Marine Inc. (QOC 6.3) · analysis
- NCRA — Nocera, Inc. (QOC 6.3) · analysis
- SRRE — Sunrise Real Estate Group, Inc. (QOC 6.3) · analysis
- SPWH — Sportsman's Warehouse Holdings, Inc. (QOC 6.3) · analysis
- ACVA — ACV Auctions Inc. (QOC 6.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does BRTX Appear In?
So Is BioRestorative Therapies, Inc. (BRTX) Worth Buying in 2026?
The convergence of 6.3/10 quality, multi-model undervaluation (1/1 bullish, +351.0% median upside), and a median fair value of $11.91 vs. $2.64 current price makes BioRestorative Therapies, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. BioRestorative Therapies, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BRTX Stock?
Should I buy BRTX stock right now?
Based on CirclFi's multi-model analysis, 1 of 1 models see upside for BRTX at $2.64. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 6.3/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in BioRestorative Therapies, Inc.?
Key risks include: limited model coverage (1/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does BRTX compare to its competitors?
Among Biotechnology peers, BRTX holds a Quality Score of 6.3/10. Comparable companies include CHRS (QOC 6.3), PHAT (QOC 6.3), IONS (QOC 6.3). The relative ranking helps investors identify whether BRTX offers better fundamental quality than alternatives in the same sector.
Is BRTX a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BRTX's Quality Score of 6.3/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy BRTX at?
CirclFi does not provide target buy prices or price alerts. However, our 1 active models produce fair value estimates ranging from $11.91 to $11.91. At $2.64, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BRTX.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad